Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 19/20 | 0.65 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4682045 | 0.96 | CCR4 (0.65) | CCR4SLC40A1 | |
| SCHEMBL5728001 | 0.92 | CCR4 (0.57) | CCR4 | |
| SCHEMBL12281891 | 0.88 | CCR4 (0.54) | CCR4 | |
| SCHEMBL5617394 | 0.87 | CCR4 (0.51) | CCR4 | |
| SCHEMBL4681259 | 0.86 | CCR4 (0.74) | CCR4 | |
| SCHEMBL2422617 | 0.85 | SLC40A1 (0.56) | CCR4SLC40A1 | |
| SCHEMBL4681633 | 0.83 | CCR4 (0.66) | CCR4 | |
| SCHEMBL4683826 | 0.83 | CCR4 (0.72) | CCR4 | |
| SCHEMBL12283537 | 0.82 | CCR4 (0.51) | CCR4SLC40A1 | |
| SCHEMBL1731557 | 0.81 | CCR4 (0.78) | CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | claimed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | claimed |
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| EP-1660461-B1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2008-10-22 | — | — | EP | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | ASTRAZENECA AB (SE) | 2007-04-26 | — | — | US | disclosed |
| EP-1660461-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | AstraZeneca AB (SE) | 2006-05-31 | — | — | EP | disclosed |
| WO-2005021513-A1 | NOVEL CONDENSED N-PYRAZINYL-SULPHONAMIDES AND THEIR USE IN THE TREATMENT OF CHEMOKINE MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2005-03-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093491-A1 | Novel condensed n-pyrazinyl-sulphonamides and their use in the treament of chemokine mediated diseases | CCL2, CCL11, CCR2 | CCR4 13/4885SLC40A1 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.